• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sens. Sanders, Cruz talk drug pricing, Obamacare in town hall debate

February 8, 2017 By Sarah Faulkner

Sens. Sanders, Cruz talk drug pricing, Obamacare in town hall debateSens. Bernie Sanders (I-Vermont) and Ted Cruz (R-Texas) met last night to debate the future of Obamacare in a town-hall debate. The 2 senators are opposed on how to provide health care coverage to Americans, but found common ground on drug pricing and pharmaceutical importation.

Sanders and Cruz agreed that people should be able to purchase drugs from other countries, suggesting that it could create an environment of competition and lower U.S. prices. In January, both senators voted for an amendment to a budget resolution that would have allowed drug re-importation, but it did not pass.

“Pharmacists and distributors should be able to buy [Food and Drug Administration] approved medicine anywhere in the world. Then you will have international competition,” Sanders said.

“The pharmaceutical industry owns the United States Congress,” he added. “It’s not just Republicans.”

While Cruz agreed, he said the process to approve a new drug must be accelerated.

“The cost of getting a new drug approved is prohibitively expensive,” he said. “Just curing cancer would save $50 trillion across the globe and the FDA is a barrier to doing that.”

While the senators were able to agree that the pharmaceutical industry and drug pricing present problems in the U.S., they did not reach common ground regarding the future of Obamacare.

Sanders pushed for a single-payer system, saying that Obamacare was a step in the right direction towards universal healthcare. Cruz, on the other hand, asserted that Obamacare failed to live up to its promises and called for commonly-touted Republican policies including the sale of insurances across state lines.

The future of Obamacare is up in the air – the Republican-controlled Congress has made it a priority to undo the former president’s healthcare legislation, but has not indicated whether it will repeal the bill and offer a replacement simultaneously or repeal without a replacement ready to go.

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: Capitol Hill

IN CASE YOU MISSED IT

  • Medtrum introduces 300-unit tubeless insulin pump
  • Baxter reports positive smart infusion pump, EMR integration data
  • Dexcom to cease G6 CGM production next year, transition fully to G7
  • Modular Medical prices $4.7M public offering
  • Medtronic studies highlight MiniMed 780G’s cost-effectiveness

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS